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Abstract: The liver as transplantation site for pancreatic islets
is associated with significant loss of islets, which can be pre-
vented by grafting in a prevascularized, subcutaneous scaf-
fold. Supporting vascularization of a scaffold to limit the
period of ischemia is challenging and was developed here by
applying liposomes for controlled release of angiogenic fac-
tors. The angiogenic capacity of platelet-derived growth fac-
tor, vascular endothelial growth factor, acidic fibroblast
growth factor (aFGF), and basic FGF were compared in a
tube formation assay. Furthermore, the release kinetics of dif-
ferent liposome compositions were tested. aFGF and L-a-
phosphatidylcholine/cholesterol liposomes were selected to
support vascularization. Two dosages of aFGF-liposomes (0.5
and 1.0 lg aFGF per injection) were administered weekly for
a month after which islets were transplanted. We observed
enhanced efficacy in the immediate post-transplant period
compared to the untreated scaffolds. However, on the long-
term, glucose levels of the aFGF treated animals started to
increase to diabetic levels. These results suggest that injec-
tions with aFGF liposomes do improve vascularization and
the immediate restoration of blood glucose levels but does
not facilitate the long-term survival of islets. Our data empha-
size the need for long-term studies to evaluate potential ben-
eficial and adverse effects of vascularization protocols of
scaffolds. VC 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part A:
105A: 2533–2542, 2017.
Key Words: type 1 diabetes, islet transplantation, controlled
growth factor release, vascularization, scaffold
How to cite this article: Smink AM, Li S, Swart DH, Hertsig DT, de Haan BJ, Kamps JAAM, Schwab L, van Apeldoorn AA, de
Koning E, Faas MM, Lakey JRT, de Vos P. 2017. Stimulation of vascularization of a subcutaneous scaffold applicable for
pancreatic islet-transplantation enhances immediate post-transplant islet graft function but not long-term normoglycemia.
J Biomed Mater Res Part A 2017:105A:2533–2542.
INTRODUCTION
Type 1 diabetic patients require daily injections of insulin
to control their blood glucose levels in addition to monitor-
ing their blood glucose several times per day. This intensive
therapy is life-saving, but cannot prevent frequent hypogly-
cemia and diabetic complications.1 These complications can
be prevented by transplanting an endogenous insulin source
such as pancreatic islets that regulate glucose levels from a
minute-to-minute level.2 Currently islets are infused into the
liver as clinical standard, but widespread application of this
therapy is limited due to the lack of long-term success:
within 5 years after clinical islet transplantation <50% of
the patients remain normoglycemic.3,4 The liver as trans-
plantation side is considered to be a major contributor to
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these low success rates. Inadequate revascularization,5 the
large numbers of natural killer T cells in the liver,6 high con-
centrations of immunosuppressive drugs,7,8 and the instant
blood-mediated inflammatory reaction9 play a role in islet
graft failure after intraportal transplantation. Therefore, a
more adequate transplantation site is required for this tech-
nology to gain widespread acceptance and practice.
The subcutaneous site might be a suitable alternative
for the liver as it is easily accessible, able to bear an
adequate tissue volume, and enables monitoring of the islet
graft after transplantation. However, up to now the efficacy
of subcutaneous islet transplantation is low due to poor
revascularization of islets in the subcutaneous site.10 During
islet isolation, the vasculature is disrupted while in the
native pancreas the islets are highly vascularized and
receive 15–20% of the pancreatic blood supply.11,12 Inad-
equate revascularization leads to hypoxia and finally to
reduced islet viability and function after transplantation.
Before the subcutaneous site could be used it might be nec-
essary to stimulate the vascularization degree in order to
accommodate the islets.10
Several biomaterials were used to modify the subcutane-
ous site to facilitate islet-survival, but resulted in variable




exerted protective effects on the viability and function of
islets and improved the engraftment of subcutaneous trans-
planted islets.14 However, compared to islet transplantation
under the kidney capsule, the PDLLCL scaffold was less effi-
cacious in achieving normoglycemia. A conceivable way to
further improve the efficacy of the PDLLCL scaffold is by
stimulating vascularization in order to reduce the distance
between the engrafted islets and blood vessels facilitating
faster ingrowth into the islets. Several strategies have been
proposed to enhance vascularization. This includes co-
transplantation of vascular-inductive cell types,15,16 delivery
of angiogenic genes,17,18 or growth factor injections.19,20
Some of these proposed systems are not applicable for
islets. For example harvesting vascular-inductive cell types
of the same donors as that of islets might be complex, while
there are safety concerns associated with the gene transfer
technology.21 By directly injecting the growth factors pro-
duced by the vascular-inductive cell types or angiogenic
genes, these issues are circumvented. However, bolus deliv-
ery of growth factors showed limited effectiveness.20,22,23
Often multiple injections of high concentrations are required
which result in abnormal vascularization and are associated
with undesired side effects such as leaky vessels, growth of
tumor-like vessels, or hemangiomas.20 Therefore, several
groups including ours focused on the development of a con-
trolled release system for angiogenic growth factors.24–27
With the aim of improving vascularization of a subcutane-
ous islet transplantation site, in this study, we compared the
angiogenic capacity of platelet-derived growth factor (PDGF),
vascular endothelial growth factor (VEGF), acidic fibroblast
growth factor (aFGF), and basic FGF (bFGF). These are all
growth factors with reported efficacy in stimulation of vascu-
larization.28 Subsequently, liposomes were designed for
delivery of the selected growth factor in the PDLLCL scaffold.
Two dosages of growth factor containing liposomes were
administered weekly for a month after which efficacy of the
subcutaneous scaffold as transplantation site for an islet graft
was compared to untreated scaffolds.
MATERIALS AND METHODS
Experimental design
The angiogenic capacity of PDGF, VEGF, aFGF, and bFGF
were first tested in vitro using a tube formation assay
(described below). For in vivo purposes, controlled release
liposomes were designed and tested in vitro for release of
the most potent angiogenic growth factor. To support vascu-
larization, subcutaneously placed PDLLCL scaffolds received
an injection with liposomes containing the angiogenic factor
on a weekly basis during a month before islets were intro-
duced. To test the efficacy of the liposome-treated scaffold
as transplantation site for islets, 800 rat islets were
implanted in scaffolds treated with liposomes loaded with
0.5 and 1.0 lg growth factor and compared with untreated
controls. Nonfasting blood glucose levels of the mice were
monitored three times a week and 2 weeks after transplan-
tation an intraperitoneal glucose tolerance test (IPGTT) was
performed.29 Islet function was monitored for 75 days after
islet transplantation. After 75 days, the scaffolds were
removed for histological analysis of the vascularization.
Cells
Human umbilical vein endothelial cells (HUVECs) were pro-
vided by the Endothelial Cell facility of the UMCG (Gro-
ningen, The Netherlands). The HUVECs were cultured in
RPMI (Lonza, Basel, Switzerland) supplemented with 2 mM
L-Glutamine (GibcoTM; Thermo Fisher Scientific, Landsmeer,
The Netherlands), 5 U/mL heparin (GibcoTM), 100 IE/mL
penicillin (GibcoTM), 100 lg/mL streptomycin (GibcoTM),
50 lg/mL crude ECGF solution (Sigma-Aldrich, Zwijndrecht,
The Netherlands) and 20% FCS (Sigma-Aldrich) at 378C and







A HUVEC tube formation assay was performed to compare
the in vitro effects of human PDGF (Life Technologies, Bleis-
wijk, The Netherlands), VEGF (Life Technologies), aFGF (Life
Technologies), and bFGF (Life Technologies) on the angio-
genic activity of vascular endothelial cells. HUVECs
(200,000 cells/mL) were plated on to growth factor reduced
MatrigelTM (BD Biosciences, Breda, The Netherlands) with
the different growth factors in a concentration of 5 ng/mL.
MatrigelTM plated HUVECs cultured in basal RPMI without
supplements served as control. After overnight incubation
at 378C and 5% CO2, the cells were stained with 1 mM cal-
cein AM (Molecular Probes; Life Technologies) and tube for-
mation was determined with a Leica DM IL fluorescent
microscope with a Leica DFC 420 camera (Leica Microsys-
tems B.V., Rijswijk, The Netherlands). The images obtained
were analyzed using ImageJ (Version 1.47f; Rasband, W.S.,
ImageJ, USA National Institutes of Health, Bethesda,
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Maryland, USA, http://imagej.nih.gov/ij/, 1997–2012). The
angiogenic activity was defined as the percentage of pixels
in an image that form the tubes (%Area), the %Area was
normalized to the controls (controls set on 1).
Liposome preparation
Liposomes composed of L-a-phosphatidylcholine (PC; Instru-
chemie B.V., Delfzijl, The Netherlands) and cholesterol
(Sigma-Aldrich) in a molar ratio of 60:40 were prepared by
lipid film hydration. Briefly, lipids were dissolved in a 9:1
v/v chloroform/methanol solution (Merck Millipore, Amster-
dam, The Netherlands) and dried under a stream of
nitrogen for 10 and 30 min of vacuum. The dried lipids
were hydrated overnight with HN buffer [5 mM HEPES
(GibcoTM), 150 mM NaCl (Merck Millipore), pH 7.4]. Lipo-
some size was reduced by repeated extrusion through a pol-
ycarbonate membrane (Whatman; Maidstone, Kent, UK)
with a pore size of 50 nm using a high-pressure extruder
(Lipex, Vancouver, Canada). The concentration of the lipo-
somes was determined by a phosphate assay. The size of
the liposomes was determined with a Nicomp 380 ZLS Par-
ticle Sizing analyzer (Nicomp particle sizing systems; Port
Richey, FL) using dynamic light scattering in the volume-
weighing mode (Table I). The liposomes were stored at 48C
under argon gas.
Growth factor release from liposomes
To determine the release pattern of growth factor from the
liposomes, liposomes were incubated in 10 lg/mL growth
factor for 60 min at 378C. To be able to take samples for
measuring the release without removing liposomes, the lipo-
somes were immobilized in an alginate microbead.30 To this
end, growth factor loaded liposomes were mixed with 1.9%
high-gluconic acid alginate (ISP Alginates, Girvan, UK) and
divided over a 96-wells plate. The alginate was crosslinked
with calcium chloride (100 mM; Merck Millipore) during
10 min incubation at room temperature. The calcium chlo-
ride was replaced with Krebs–Ringer–Hepes (KRH; pH 7.4,
133 mM NaCl, 4.69 mM KCl, 1.18 mM KH2PO4, 1.18 mM
MgSO4.7H2O, 25 mM HEPES, 2.52 mM CaCl2.2H2O (all
obtained from Merck Millipore)) solution and the release
experiment was carried out at 378C and 5% CO2 for
14 days. The KRH was replaced first after one hour, and
then every 24 h. These samples were used for quantification
of the growth factor and were stored at 2208C. QuantikineV
R
Human ELISA (R&D Systems, Oxon, UK) was performed
according to manufacturers’ protocol to determine the
growth factor concentrations in the samples.
Scaffold preparation
Porous PDLLCL scaffolds were obtained from Polyganics B.V.
(Groningen, The Netherlands). Briefly, PDLLCL was dissolved
in chloroform (Merck Millipore; 4% (w/v)) and thoroughly
mixed with 250–425 lm sodium chloride particles (Sigma-
Aldrich; 10:1 w/w). The solvent was allowed to evaporate
overnight. To remove the sodium chloride particles from the
5 mm thick polymer sheet, it was washed thoroughly with
sterile water. The porous polymer sheet was resized into 10
by 15 mm rectangle scaffolds. During the casting process
two channels were created by introducing 400 lm iron
rods. After casting, these iron rods were substituted by
hydrophobic polyethylene tubing (PE50, 0.5 3 1 mm; Brink-
man, ‘s-Gravenzande, The Netherlands) that keep the chan-
nels patent during the 4 weeks of engraftment of the
scaffold in the mice recipients. The scaffolds were washed
and stored in 70% ethanol (Fresenius Kabi, Zeist, The Neth-
erlands) before implantation.
On the day of implantation the pores of the scaffolds
were filled with fibrin. This was done by adding 1 lL
thrombin IIa (1.0 U/mL; Stago, Leiden, The Netherlands) to
100 ll fibrinogen (2 mg/mL; Stago) solution. During a 1 h
incubation at room temperature and a 1 h incubation at
378C, the fibrin gel was solidified in the pores of the
scaffold.
Islet isolation
The study was conducted according to the NIH guidelines
for the care and use of laboratory animals (NIH Publication
#85–23 Rev. 1985). The University of California Institutional
Animal Care and Use Committee at the University of Irvine
approved the beneath described animal procedures for islet
isolation and transplantation (IACUC # 2008–2850). Male
Sprague-Dawley rats (Harlan, Placentia, USA) with a body
weight of 250–279 g served as pancreas donors for islet
isolation. Briefly, under anesthesia pancreata were distended
with Collagenase V (Sigma-Aldrich) in Hank’s balanced salt
solution (HBSS; Corning Cellgro, Virginia) and carefully dis-
sected. The distended pancreata were incubated for 18 min
at 378C. After several washes, islets were separated from
the exocrine tissue by making use of a Ficoll (Gradient stock
solution; Corning Cellgro) density-gradient. Islet yield and
purity were quantified by a dithizone staining (MP Biomedi-
cals, Santa Ana).
Islet transplantation
Male athymic nude mice (Foxn1nu; Charles River, Wilming-
ton, USA) of 8 weeks old were used as transplant recipients.
The nude mice were rendered diabetic by an intraperitoneal
streptozotocin (Sigma-Aldrich) injection of 180 mg/kg. Dia-
betes was confirmed by a minimum of three consecutive
measurements of blood glucose above 350 mg/dL. A Bayer
Health Care (Whippany, USA) blood glucose monitor was
used to measure nonfasting blood glucose levels. After dia-
betes confirmation, the mice received an insulin implant
(LinBit; LinShin, Scaraborough, Canada) to reduce the dis-
comfort caused by the diabetic state and PDLLCL scaffolds
were subcutaneously implanted on the upper back of the
TABLE I. Liposome Characteristics
Lipids Molar Ratio Size (nm)
Concentration
(lmol TL/ml)
PC:CHOL 60:40 67.9 6 31.7 12.1 6 1.9
The size and concentration (mean 6 standard deviation) of lipo-
somes composed of L-a-phosphatidylcholine (PC) and cholesterol
(CHOL). The concentration is expressed is the total amount of both
PC and CHOL lipids (TL) per ml.
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mice 4 weeks before transplantation. The skin was closed
using a standard two-layer technique with 3–0 silk sutures
(Ethicon, San Angelo, USA) and skin staples (Cellpoint Scien-
tific, Gaithersburg, USA). To stimulate growth of vasculature
in and around our scaffold we made use of growth factor-
loaded liposomes. Liposomes were loaded with growth fac-
tor by an incubation of 60 min at 378C. Liposomes were
loaded with a 10 lg/mL growth factor solution and subcu-
taneously injected near the implanted scaffold. Injections
were started at the day of scaffold implantation and were
repeated three more times after every 7 days.
At the day of islet transplantation, the mice were anes-
thetized by 2–3% of isoflurane (Piramel Healthcare, Mor-
peth, UK) and a small incision was made at one side of the
preimplanted scaffold. The polyethylene tubing was
removed and 800 islets were carefully placed in two chan-
nels through a PE50 tube connected to a 23G Hamilton
syringe (SGE Analytical Science, Austin, USA). The insulin
implant was removed directly after transplantation in all
groups and all mice received ibuprofen (Banner Pharma-
caps, High Point, USA; 0.2 mg/mL) as analgesic postsurgery
for 2 days.
The nonfasting blood glucose levels were measured on a
weekly basis to monitor the function of the islet graft. Ani-
mals were considered to be normoglycemic when blood glu-
cose levels were below 150 mg/dL. When the blood glucose
levels remained above 350 mg/dL or higher, the animal was
euthanized by a cut through the heart and the scaffold was
removed for histological analysis.
Intraperitoneal glucose tolerance test
To determine the metabolic graft function in terms of glucose
clearance, an IPGTT was performed in the second week after
islet transplantation.29 Before the IPGTT was started, mice
were fasted overnight. At time point 0 an intraperitoneal glu-
cose (3 g/kg; Sigma-Aldrich) injection was given to these
mice. To determine the glucose concentration in the blood at
time points 0, 10, 30, 60, 90, and 120 min after this injection,
blood samples were collected from the tail and glucose con-
centration was measured with a Bayer Health Care blood glu-
cose monitor. For analysis the glucose clearance was
expressed as the area under the curve (AUC).31
Histological examination
The scaffolds were removed 75 days after islet transplanta-
tion. After removal, the nonfasting blood glucose levels were
measured for another week to determine graft dependency
of the normoglycemia. After this week, the animals were
sacrificed. Pancreas biopsies were taken to exclude pancreas
regeneration. The islet scaffolds were fixed in fresh 2%
paraformaldehyde (Merck Millipore) and processed for gly-
col methacrylate (GMA; TechnovitV
R
8100; Heraeus Kulzer
GmbH, Wehrheim, Germany) embedding. Sections of 2 lm
were used for insulin staining. Briefly, sections were dried
at 378C and incubated in 0.01% trypsin [Sigma-Aldrich; in
6.8 mM 0.1% CaCl2 (Merck Millipore) and 0.1M Tris–HCl
(Merck Millipore), pH 7.8] for 10 min at 378C. The sections
were incubated with a mouse antirat insulin antibody
[Sigma-Aldrich; 1:300 in PBS (Lonza) 1 1% BSA (Sigma-
Aldrich)] for 2 h at 378C. After this incubation, the staining
procedure was performed at 208C. Nonspecific binding was
blocked by 5 min incubation with 10% normal rabbit serum
(Sigma-Aldrich). The secondary rabbit antimouse alkaline
phosphatase conjugated antibody (Dako, Heverlee, Belgium;
1:100 in PBS 1 1% BSA) was applied for 45 min. Alkaline
phosphatase activity was demonstrated by incubating the
sections for 10 min with SIGMAFASTTM Fast Red (Sigma-
Aldrich). A short incubation with hematoxylin (Sigma-
Aldrich) was used as counterstain. Furthermore, to observe
inflammation and vascularization GMA sections were
stained with 1% (w/v) aqueous toluidine blue (Fluka Chem-
ika, Buchs, Switzerland) for 10 s.
The pancreas biopsies were processed for paraffin imbe-
dding. Sections of 5 lm were used for an aldehyde fuchsin
staining to determine the presence of viable of beta cells.32
Briefly, sections were oxidized by 2.5% KMnO4 (Sigma-
Aldrich) and 5% H2SO4 (Merck) in demineralized water for
90 s and cleaned with 2% oxalic acid (Sigma-Aldrich) for
2 min. After an incubation of 2 min with 70% ethanol, sec-
tions were incubated with aldehyde fuchsin solution32,33 for
10 min. An incubation of 6 min with Halmi [0.2% Light-
green SF (Sigma-Aldrich) 1 1% Orange G (Sigma-
Aldrich) 1 0.5% Chromotrope 2 R (Sigma-Aldrich) 1 0.5%
H2WO4 (Sigma-Aldrich) 1 1% CH3COOH 100% (Merck
Millipore) in demi water] was used as counterstain. The
absence of beta-cell regeneration in the native pancreas was
defined as <5% of normal controls. All above-mentioned
stained sections were analyzed using a Leica DM 2000 LED
microscope with a Leica DFC 450 camera (Leica Microsys-
tems BV).
Statistical analysis
Statistical analysis was carried out in GraphPad Prism (ver-
sion 5.0b; GraphPad Software, La Jolla, USA). A Shapiro–Wilk
normality test was performed to test the data for normality.
For statistical analysis of the tube formation assay and IPGTT
data a Kruskal–Wallis test with a Dunn’s post hoc test was
applied, p < 0.05 were considered significant. The data are
respectively presented in mean 6 standard deviation in case
of parametric distribution and median 6 interquartile range
in case of nonparametric data distribution.
RESULTS
Superior angiogenic capacity by aFGF
Angiogenic growth factors with reported efficacy in stimu-
lating vascularization28 were compared. To this end, PDGF,
VEGF, aFGF, and bFGF were compared in a HUVEC tube for-
mation assay (Fig. 1). The formation of tubes [median
%Area (quartile range)] was not stimulated by PDGF
[1.1%Area (0.7–1.3)] and VEGF [1.0%Area (0.9–1.3)]; the
tube forming capacity of these growth factors was similar to
the control condition (set on 1). Addition of aFGF resulted
in a two-fold increase of tube formation, 2.0%Area (1.5–
2.5). This increase was significantly higher than the %Area
of PDGF and VEGF (p < 0.05). Furthermore, bFGF slightly
enhanced the tube formation to 1.3%Area (1.2–1.6). Based
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on these results, aFGF was selected for the follow up
experiments.
Design of liposomes for controlled release of aFGF
For delivery of the growth factor over a longer time period,
liposomes were applied. As the release kinetics and loading
capacity of liposomes can vary, several compositions of lipo-
somes were tested.34 Based on previous studies with
growth factor containing liposomes,26,35 we tested in vitro
liposomes composed of 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (POPC)/PC/cholesterol in a molar ratio of
50:50:5, PC/phosphatidylglycerol (PG)/cholesterol in a
molar ratio of 50:50:5, and PC/cholesterol in a molar ratio
of 60:40. The growth factor release kinetics of these three
types of liposomes were determined and found to be simi-
lar. PC/cholesterol (60:40) liposomes were able to load
slightly higher amounts of growth factor. The PC/cholesterol
liposomes were therefore selected for the follow up experi-
ments with aFGF.
The duration of release of aFGF was monitored in vitro
to test if we obtained a sustained release of the growth fac-
tor (Fig. 2). At the start (day 0), liposomes released 5.2 ng/
mL (4.0–6.7) aFGF and during the first 2 days the level was
stable at 4.7 ng/mL (2.5–6.7). At day 3, the aFGF concentra-
tion decreased to 3.0 ng/mL (1.0–4.6) and this decrease
continued till day 5, then the release stabilized at 0.7 ng/
mL (0.1–1.3). From day 8 the concentration dropped below
0.5 ng/mL (0.1–0.9), slowly further decreasing till 0.4 ng/
mL (0.3–0.5) at day 14. The total amount of aFGF released
during the 14 days was 23.8 ng/mL (16.1–29.3).
Restoration of blood glucose levels immediate following
transplantation
Complete normoglycemia after rat islet transplantation was
defined as blood glucose levels below 150 mg/dL. An islet
graft of 800 islets was transplanted in PDLLCL scaffolds
after a prevascularization period of 4 weeks. During this
prevascularization period liposomes were injected once a
week near the scaffold. The control group received a weekly
injection of 100 lL empty liposomes. The 0.5 lg aFGF group
received a 100 lL aFGF-loaded liposome injection and the
1.0 lg aFGF group received 200 lL aFGF loaded liposomes.
The concentrations were chosen because 0.5 lg aFGF was
most effective in enhancing the tube formation and in previ-
ous studies concentrations of 0.5–1.0 lg aFGF showed to
improve islet engraftment.36,37 Efficacy of the 800 islet-dose
in sham-injected scaffolds was compared with that of scaf-
fold treated with liposomes containing either 0.5 or 1.0 lg
aFGF.
From the animals that received empty liposome injec-
tions 40% became normoglycemic within 15.5 6 10.6 days
(mean 6 standard deviation) (Table II). This percentage
increased up to 50% with a dose of 0.5 lg aFGF. The ani-
mals of this group became normoglycemic within
7.0 6 8.5 days. Normoglycemia was obtained within
14.0 6 11.0 days in 80% of the animals when the dose of
aFGF was increased to 1.0 lg aFGF liposomes in the prevas-
cularization period.
aFGF administration is not compatible with long-term
maintenance of normoglycemia
The animals with a successful graft after empty liposome
injections remained normoglycemic for the duration of the
study, which was a period of 75 days (Fig. 3). Although
treatment with aFGF induced a faster return to normoglyce-
mia, we observed an impediment in long-term efficacy of
aFGF on graft function. The two animals treated with 0.5 lg
aFGF in liposomes became normoglycemic for a period of
37.5 6 1.5 days. After this period, blood glucose levels
started to increase for this group. This happened after
36 days for just one of the four animals of the 1.0 lg aFGF
group, the other three of this group remained normogly-
cemic for the duration of the experiment. This illustrates
the aFGF concentration dependent effect. After 75 days, the
islet grafts were removed and all animals returned to their
FIGURE 1. The effect of PDGF, VEGF, aFGF, and bFGF on the angio-
genic capacity of HUVECs in a tube formation assay. PDGF, VEGF,
aFGF, and bFGF were added to HUVECs for 24 h in a concentration of
5 ng/ml. The angiogenic activity was defined as the percentage of pix-
els that form tubes (%Area), the %Area was normalized to the control
(control set on 1). HUVECs cultured in basal media without supple-
ments were used as control. Median and interquartile range are plot-
ted (n 5 5), a statistical analysis was carried out using a Kruskal–
Wallis test with a Dunn’s post hoc test, p < .05 (*).
FIGURE 2. aFGF release from liposomes. The absolute release of
aFGF from our liposomes during 14 days of incubation. Each well
contained 0.6 lmol (60.1) PC:CHOL liposomes and every day the
200 ll KRH was replaced. Data are plotted as median and interquartile
range (n 5 4).
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pretransplant hyperglycemic state (Fig. 3). As an additional
control pancreas biopsies were studied but no regeneration
was observed.
Glucose tolerance changed over time
To test the metabolic function of the islet grafts an IPGTT
was performed in the second week after transplantation
(Fig. 4). After 2 weeks, both aFGF groups (0.5 and 1.0 lg)
had a worse glucose clearance of respectively 20,445 (mg/
dL) 3 min (19,505–21,385) and 29,220 (mg/dL) 3 min
(22,130–31,424) compared to the control group (0 lg
aFGF). The glucose clearance of the control group after
2 weeks was 15,180 (mg/dL) 3 min (13,746–16,614). The
twofold increase after injections of 1.0 lg aFGF compared to
the empty liposomes was statistically significant (p < 0.05).
Histology
At the end of the experiment, differences were found
between the histopathology of the different aFGF treatment
groups. The control group, treated with empty liposomes,
contained large numbers of insulin positive islets with a
normal spherical shape, positioned in the clearly visible
channels [Fig. 5(A,B)]. The islet channels were kept patent
during the preimplantation period by polyethylene tubing
and after 75 days the place of the tubing was easily found
by the cell ingrowth into these channels. In the 0.5 lg aFGF
group, a small number of insulin positive islets were found
after 75 days [Fig. 5C,D]. However, large numbers of insulin
positive islets were found in the 1.0 lg aFGF scaffold group
[Fig. 5(E,F)].
Toluidine blue staining showed increased vascularization
in the aFGF groups compared with the control group (Fig.
6). The number of blood vessels within the scaffold was
enhanced in a dose-dependent matter [Fig. 6(A–C)]. In the
scaffolds we found no differences in inflammation. Similar
amounts and types of inflammatory cells were found in the
scaffold. However, at the site where the liposomes were
injected, a lot of collagen deposition was observed [Fig.
6(D)].
DISCUSSION
By applying a stepwise approach in which we compared the
angiogenic capacity of VEGF, PDGF, aFGF, and bFGF, and dif-
ferent liposome formulations, we designed a controlled
release system for supporting vascularization. With this
delivery system we were able to enhance the efficacy of our
subcutaneous PDLLCL scaffold as transplantation site for
islets in the immediate post-transplant period. The positive
effects in the immediate post-transplant period were aFGF
concentration dependent. However, long-term function was
not improved by the vascularization protocol and was even
worse in the aFGF treated scaffolds. After approximately
36 weeks the nonfasting blood glucose levels of the aFGF
treated animals started to increase to diabetic levels, which
did not happen in the untreated scaffolds. It was due to
aFGF treatment and not by the liposomes injections as the
controls received sham injections with empty liposomes and
TABLE II. Transplantation Success Rate
0 lg aFGF 0.5 lg aFGF 1.0 lg aFGF
Days: Cure Rate: Days: Cure Rate: Days: Cure Rate:
15.5 6 10.6 2/5 (40%) 7.0 6 8.5 2/4 (50%) 14.0 6 11.0 4/5 (80%)
The mean of days 6 standard deviation post transplantation until normoglycemia occurs. Blood glucose values under 150 mg/dL were con-
sidered normoglycemic and therefore, also as a successful cure.
FIGURE 3. Nonfasting blood glucose post transplantation and aFGF
injections. Blood glucose levels measured after islet transplantation
into the subcutaneous scaffold. Normoglycemia was defined as blood
glucose levels below 150 mg/dL (dotted line). The control group
received empty liposomes (0 lg aFGF, blue line) on a weekly basis
during 4 weeks before islet transplantation, the 0.5 lg group received
liposomes loaded with 0.5 lg aFGF (black line), and the 1.0 lg group
received the double amount of liposomes loaded with 0.5 lg aFGF
(red line). After 75 days the scaffolds including the islet graft were
removed (arrow). Blood glucose mean and standard deviation are
plotted (n 5 2 for 0 and 0.5 lg aFGF groups, n 5 4 for 1.0 lg aFGF).
FIGURE 4. Glucose clearance after intraperitoneal glucose tolerance
test. At 2 weeks after islet transplantation into the scaffolds, the glu-
cose clearance was measured, this is expressed as area under the
curve (mg/dL 3 min) for the 0 lg aFGF (control), 0.5 lg aFGF, and
1.0 lg aFGF groups. Data are plotted as median and interquartile range
(n 5 5), statistical differences between the groups were measured with
a Kurskal–Wallis test with a Dunn’s post hoc test, p < 0.05 (*).
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remained normoglycemic. Furthermore, the IPGTT data
showed that addition of aFGF did not improve the glucose
clearance compared with the control.
We hypothesize that the vessels and endothelium
attracted by aFGF have a different phenotype. More permea-
ble may be an option but it is difficult to proof. We tried
many things to identify the cause for long-term failure. One
of the first things was a detailed study on the cell infiltrates
and possible immune cells. We found no differences between
the controls and aFGF treated scaffolds. This is also not a log-
ical explanation as immediate graft function was improved
by aFGF. A proinflammatory microenvironment results in
slower return and not faster return to normoglycemia. We
think is has to do with differences in the vessel phenotype.
An explanation for the difference in effects of aFGF
administration in the immediate and long-term period might
be that growth factors such as aFGF induce immediate vas-
cularization, but that for sustained maintenance of the bene-
ficial environment more or other angiogenic factors are
required. This suggestion is corroborated by the observa-
tions of McQuilling et al.25 and Khanna et al.26 who found
enhanced vascularization for aFGF-containing capsules
implanted into the omental pouch. However, transplantation
of islets in these aFGF microcapsules in the omental pouch
FIGURE 5. Insulin positive islets after 75 days in the scaffolds. Insulin staining (SIGMAFASTTM Fast Red) of 800 islets in the nontreated subcuta-
neous PDLLCL scaffold (A, 53; B, 203) 75 days after transplantation. The place of the islet channel (black lines) was clearly visible (A, E). A small
number of insulin positive cells was found after 75 days in the 0.5 lg aFGF groups (C, 53; D, 203). Insulin positive cells (E, 53; F, 203) 75 days
after transplantation into a scaffold treated with 1.0 lg aFGF.
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did not result in better transplantation outcomes, c-peptide
levels, and glycemic control was less beneficial than in con-
trols not containing aFGF.36 Their data and ours suggest
that establishment of a stable vascular network is complex
and might require several angiogenic factors to promote
vessel sprouting and remodeling of the vascular network.38
This is supported by clinical studies demonstrating even
detrimental effects after injections of a single growth
factor.39–41
Liposome injections may also have a negative effect on
graft outcome in our study, since in our previous study,42
transplantation of 800 islets into the preimplanted PDLLCL
scaffold (in the absence of liposomes) induced normoglyce-
mia in 80% of the recipients. This was only 40% in the cur-
rent study where controls received empty liposomes. The
large amount of collagen deposition observed in this study
was not found in the previous study. This suggests that the
four injection procedures or the characteristics of liposomes,
that is, size, composition, surface properties, and charge,
disturb the scaffold environment before transplantation.
Therefore, our liposomes may not have the optimal charac-
teristics for growth factor delivery before islet transplanta-
tion. In further research, these characteristics should be
optimized. The liposomes itself should not negatively influ-
ence the vascularization process and ideally they should
release growth factor for a month to exclude the multiple
injections. After optimization of the liposomes, it could even
be possible to immobilize the liposomes in the scaffold to
discard the injections.
Acidic fibroblast growth factor is used in several clinical
trials to promote angiogenesis for the treatment of diseases,
such as spinal cord injury,43 coronary artery disease,44 and
critical limb ischemia.45 In this study, we demonstrated the
superior angiogenic capacity of aFGF in the HUVEC tube for-
mation assay. This was described before for endothelial cell
assays.46 To our opinion it is remarkable that in many stud-
ies VEGF is used as angiogenic therapeutic. VEGF is also
known as vascular permeability factor and was initially
described to induce vascular leakage and permeability
besides its ability to promote proliferation of endothelial
cells.38,47 We propose to use aFGF as VEGF seems to be
involved in the initial permeabilization of vessels and less in
tube formation and further maturation of vessels. We are
aware that any in vitro assay is not more than an indication
of what happens in vivo. In general, the tube formation
assay is considered to be a quick and quantifiable way of
measuring angiogenesis in vitro.48,49 It is a useful method to
determine growth factors that potentially play a role in vivo
vascularization. This assay was applied to select the most
efficacious growth factor, as it is impossible to test all the
factors in vivo. Also the in vitro growth factor release from
liposomes does not reflect the release kinetics in vivo. How-
ever, this method is suitable for determining if we obtained
a sustained release of growth factor.
FIGURE 6. Histology 75 days after transplantation. Toluidine blue staining (203) of scaffolds from the control group (A), 0.5 lg aFGF (B), and the
1.0 lg aFGF (C) group. Arrows indicate the blood vessels. (D) (203) depicts the collagen deposition around the scaffolds (*).
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Vascularization can occur by several mechanisms, includ-
ing vasculogenesis and angiogenesis. Vasculogenesis occurs
when endothelial progenitor cells migrate and form new
blood vessels, whereas angiogenesis is the formation of new
blood vessels from pre-existing blood vessels.38,50 Vasculo-
genesis forms a primitive tubular network, but needs angio-
genesis for forming a stable vascular system suggesting that
both mechanisms are involved in vascularization of the scaf-
fold. Vasculogenesis starts with the mobilization of angio-
blasts from the bone marrow by factors such as VEGF. The
circulating angioblasts are recruited to the site of vasculari-
zation, where they differentiate and proliferate to form a
vascular network. Angiogenesis is also initiated by growth
factors, such as FGF and VEGF, resulting in the secretion of
proteases and plasminogen activators by endothelial cells.
These secreted factors increase the permeability of the ves-
sels to allow migration of proliferating endothelial cells into
the surrounding tissue. Angiopoietin-1 and ephrin-B2 are
important for further maturation and remodeling of migrat-
ing endothelial cells into vessels. Angiopoietin-1 also main-
tains quiescence and stability after maturation of the
vessels.38,50 We believe that both pathways are important
for a stable vascular network within our scaffold.
Our findings demonstrate that injections with aFGF lipo-
somes do improve the immediate restoration of blood glu-
cose levels but do not facilitate the long-term engraftment
of transplanted islets in our PDLLCL scaffold or improve
transplant efficacy in the subcutaneous site. For further
research, combinations vasculogenesis and angiogenesis
should be tested on long-term survival of islets in scaffolds.
Weidling et al.51 developed a technology by which vasculari-
zation can be observed in real time and in a noninvasive
manner. This technology will give us more insight in the
development of stable vasculature and will be helpful in
testing different strategies to deliver growth factors.
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